Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback